Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

View All Documentation

Y0000750

Dorzolamide for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Dorzolamide hydrochloride

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C10H16N2O4S3 · HCl
Número CAS:
130693-82-2
Peso molecular:
360.90
Beilstein:
5896026
Número MDL:
MFCD00884659
Código UNSPSC:
41116107
ID de substância PubChem:
329831128
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

dorzolamide

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

chave InChI

OSRUSFPMRGDLAG-QMGYSKNISA-N

Informações sobre genes

human ... CA2(760)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Dorzolamide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0000726

Dorzolamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

1225281

Dorzolamide hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000727

Dorzolamide Impurity A, European Pharmacopoeia (EP) Reference Standard

1225292

Dorzolamide hydrochloride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1225306

Dorzolamide Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP1069

Dorzolamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR1925

Dorzolamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP1071

Dorzolamide impurity D, British Pharmacopoeia (BP) Reference Standard

BP1070

Dorzolamide impurity B, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Warning

Frases de perigo

H302,H373

Classificações de perigo

Acute Tox. 4 Oral - STOT RE 2

Órgãos-alvo

Central nervous system,Gastrointestinal tract,Bone,Blood,Bladder

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Yasuhiro Ikeda et al.
The British journal of ophthalmology, 97(9), 1187-1191 (2013-06-21)
To evaluate the therapeutic effect of continuous treatment with topical dorzolamide (a carbonic anhydrase inhibitor) for cystoid macular oedema (CME) associated with retinitis pigmentosa (RP). 18 eyes in 10 patients with CME secondary to RP were included. Baseline visual acuity
Yasuhiro Ikeda et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 250(6), 809-814 (2012-01-05)
Cystoid macular edema (CME) is one of the common complications of retinitis pigmentosa (RP), and is responsible for patient complications such as blurred and reduced visual acuity and for subsequent atrophic changes in the fovea. The objective of this work
Ikuyo Ohguro et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 392-396 (2012-04-07)
The purpose of the present study is to evaluate the effects of a fixed combination of 0.5% timolol maleate (TM) and 1% dorzolamide hydrochloride (DZ) (FCTD(1%)) on optic nerve head (ONH) blood circulation. A drop of 0.5% TM, 1% DZ
Vikas Gulati et al.
Archives of ophthalmology (Chicago, Ill. : 1960), 130(6), 677-684 (2012-02-15)
To evaluate the interaction of intraocular pressure(IOP)–lowering medications with physiologic day and night changes in aqueous humor dynamics in participants with ocular hypertension. Thirty participants were enrolled in thisdouble-masked, randomized, crossover study. Each participant underwent aqueous humor dynamics measurements at
Mumin Hakan Eren et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 381-386 (2012-02-11)
To compare the efficacy and safety of dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC) with latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC) on diurnal intraocular pressure (IOP) in patients with primary open-angle glaucoma. Thirty-three primary open-angle glaucoma patients with
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica